Clinical trial of serum miR-499 and miR-652 for early diagnosis of acute coronary syndrome
10.3969/j.issn.1674-8115.2017.09.007
- VernacularTitle:血清miR-499和miR-652用于急性冠脉综合征早期诊断的临床试验
- Author:
min Hui CAO
1
;
sha Sha YOU
;
chen Yu XUE
;
Bin HE
Author Information
1. 上海交通大学 医学院附属新华医院麻醉与重症医学科
- Keywords:
microRNA;
acute coronary syndrome;
miR-499;
miR-652;
troponin I;
biomarker;
clinical trial
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2017;37(9):1225-1230
- CountryChina
- Language:Chinese
-
Abstract:
Objective·To investigate the potential value of serum miRNAs for early diagnosis of acute coronary syndrome (ACS). Methods·Blood samples were collected from 28 emergency patients with suspected ACS in 3 h after enrollment. Eighteen patients were finally diagnosed as ACS and ten as non-ACS according to the ACS guideline. The expression levels of cardiac miR-499 and myocardial injury related miR-652 were measured with qRT-PCR. At the same time levels of troponin I (cTnI) were monitored. Then the correlations between miRNAs and cTnI were analyzed. In addition, 95% reference range was established. Results·The expression levels of serum miRNAs increased in ACS patients within 3 h and serum miR-499 in the ACS patients was 9.2 times the amount in the non-ACS patients (P=0.009). Serum miR-499 (r=0.595, P=0.001) and miR-652 (r=0.579, P=0.001) levels both had positive correlations with cTnI. The area under the ROC curve (AUC) of serum miR-499 and miR-652 was 0.786 and 0.583, respectively. The sensitivity and specificity of miR-499 were 72.22% and 80.00%, respectively, while 72.22% and 60.00% for miR-652. The reference ranges of serum miR-499 and miR-652 were 0.001-2.723 and 0.122-9.660, respectively. Conclusion·Cardiac miR-499 in serum has potential to be a biomarker for early diagnosis of ACS.
